241 related articles for article (PubMed ID: 26073249)
21. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases.
Atienza-Mateo B; Martín-Varillas JL; Calvo-Río V; Demetrio-Pablo R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adan A; Hernández MV; Hernández-Garfella M; Valls-Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero-Coma M; Díaz-Llopis M; Gallego R; García-Serrano JL; Ortego-Centeno N; Herreras JM; Fonollosa A; Garcia-Aparicio ÁM; Maíz-Alonso O; Blanco A; Torre-Salaberri I; Fernandez-Espartero C; Jovaní V; Peiteado D; Pato E; Cruz J; Férnandez-Cid C; Aurrecoechea E; García-Arias M; Castañeda S; Caracuel-Ruiz MA; Montilla-Morales CA; Atanes-Sandoval A; Francisco F; Insua S; González-Suárez S; Sanchez-Andrade A; Gamero F; Linares Ferrando LF; Romero-Bueno F; García-González AJ; González RA; Muro EM; Carrasco-Cubero C; Olive A; Prior Á; Vázquez J; Ruiz-Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernandez S; Fernández-Carballido C; Rubio-Romero E; Pages FA; Toyos-Sáenz de Miera FJ; Martinez MG; Díaz-Valle D; López Longo FJ; Nolla JM; Álvarez ER; Martínez MR; González-López JJ; Rodríguez-Cundin P; Hernández JL; González-Gay MA; Blanco R
Arthritis Rheumatol; 2019 Dec; 71(12):2081-2089. PubMed ID: 31237427
[TBL] [Abstract][Full Text] [Related]
22. An open-label, prospective, single-arm study of switching from infliximab to cyclosporine for refractory uveitis in patients with Behçet's disease in long-term remission.
Ida Y; Takeuchi M; Ishihara M; Shibuya E; Yamane T; Hasumi Y; Kawano S; Kimura I; Mizuki N
Jpn J Ophthalmol; 2021 Nov; 65(6):843-848. PubMed ID: 34586526
[TBL] [Abstract][Full Text] [Related]
23. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease.
Yamada Y; Sugita S; Tanaka H; Kamoi K; Kawaguchi T; Mochizuki M
Br J Ophthalmol; 2010 Mar; 94(3):284-8. PubMed ID: 19692382
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet's disease: a large-scale, long-term postmarketing surveillance in Japan.
Ohno S; Umebayashi I; Matsukawa M; Goto T; Yano T
Arthritis Res Ther; 2019 Jan; 21(1):2. PubMed ID: 30611312
[TBL] [Abstract][Full Text] [Related]
25. Improvement of neurological and ocular symptoms of Behçet's disease after the introduction of infliximab.
Barešić M; Reihl M; Habek M; Vukojević N; Anić B
Rheumatol Int; 2018 Jul; 38(7):1301-1306. PubMed ID: 29777341
[TBL] [Abstract][Full Text] [Related]
26. A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet's syndrome.
Horiguchi N; Kamoi K; Horie S; Iwasaki Y; Kurozumi-Karube H; Takase H; Ohno-Matsui K
Sci Rep; 2020 Dec; 10(1):22227. PubMed ID: 33335139
[TBL] [Abstract][Full Text] [Related]
27. Botulinum toxin-induced acute anterior uveitis in a patient with Behçet's disease under infliximab treatment: a case report.
Sasajima H; Yagi S; Osada H; Zako M
J Med Case Rep; 2017 May; 11(1):124. PubMed ID: 28468639
[TBL] [Abstract][Full Text] [Related]
28. Long-term efficacy and safety of infliximab in the treatment of Behçet's disease.
Capella MJ; Foster CS
Ocul Immunol Inflamm; 2012 Jun; 20(3):198-202. PubMed ID: 22486265
[TBL] [Abstract][Full Text] [Related]
29. Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study.
Interlandi E; Leccese P; Olivieri I; Latanza L
Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S58-62. PubMed ID: 25005224
[TBL] [Abstract][Full Text] [Related]
30. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy.
Keino H; Okada AA; Watanabe T; Taki W
Br J Ophthalmol; 2011 Sep; 95(9):1245-50. PubMed ID: 21183514
[TBL] [Abstract][Full Text] [Related]
31. [Infliximab treatment trial in a patient with neuro-Behçet's disease unresponsive to other treatments].
Kadowaki S; Matsuda N; Moriya A; Ebitani M; Yoshihara A; Nakamura K; Mochizuki H; Ugawa Y
Rinsho Shinkeigaku; 2011 Apr; 51(4):261-6. PubMed ID: 21595295
[TBL] [Abstract][Full Text] [Related]
32. INTRAVITREAL INFLIXIMAB IN REFRACTORY UVEITIS IN BEHCET'S DISEASE: A Safety and Efficacy Clinical Study.
Hamza MM; Macky TA; Sidky MK; Ragab G; Soliman MM
Retina; 2016 Dec; 36(12):2399-2408. PubMed ID: 27870802
[TBL] [Abstract][Full Text] [Related]
33. Long-term remission of ocular and extraocular manifestations in Behçet's disease using infliximab.
Handa T; Tsunekawa H; Yoneda M; Watanabe D; Mukai T; Yamamura M; Iwaki M; Zako M
Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S58-63. PubMed ID: 21968238
[TBL] [Abstract][Full Text] [Related]
34. Uveitis in juvenile Behçet's disease: clinical course and visual outcome compared with adult patients.
Kramer M; Amer R; Mukamel M; Snir M; Jaouni T; Friling R
Eye (Lond); 2009 Nov; 23(11):2034-41. PubMed ID: 19151650
[TBL] [Abstract][Full Text] [Related]
35. Clinical course of patients with Behçet's uveitis following discontinuation of infliximab therapy.
Kawaguchi T; Kawazoe Y; Kamoi K; Miyanaga M; Takase H; Sugita S; Mochizuki M
Jpn J Ophthalmol; 2014 Jan; 58(1):75-80. PubMed ID: 24129677
[TBL] [Abstract][Full Text] [Related]
36. Biologic Treatment Options for Retinal Neovascularization in Behçet's Disease.
Markomichelakis NN; Aissopou EK; Maselos S; Tugal-Tutkun I; Sfikakis PP
Ocul Immunol Inflamm; 2019; 27(1):51-57. PubMed ID: 28700280
[TBL] [Abstract][Full Text] [Related]
37. Anti-TNF-alpha therapy for sight threatening uveitis.
Lindstedt EW; Baarsma GS; Kuijpers RW; van Hagen PM
Br J Ophthalmol; 2005 May; 89(5):533-6. PubMed ID: 15834077
[TBL] [Abstract][Full Text] [Related]
38. [A case report of malignant lymphoma receiving infliximab therapy with Behçet's disease].
Sonoda KH; Fukuhara T; Yoshikawa H; Takeda A; Yoshimura T; Akahoshi M; Kusumoto H; Kohno K; Kato K; Akashi K; Kohashi K; Aijima S; Namba K; Ishibashi T
Nippon Ganka Gakkai Zasshi; 2014 May; 118(5):440-5. PubMed ID: 25011243
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of Infliximab for Early Remission Induction in Refractory Uveoretinitis Associated with Behçet Disease: A 2-year Follow-up Study.
Keino H; Okada AA; Watanabe T; Nakayama M; Nakamura T
Ocul Immunol Inflamm; 2017 Feb; 25(1):46-51. PubMed ID: 27767359
[TBL] [Abstract][Full Text] [Related]
40. A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.
Hirano T; Ohguro N; Hohki S; Hagihara K; Shima Y; Narazaki M; Ogata A; Yoshizaki K; Kumanogoh A; Kishimoto T; Tanaka T
Mod Rheumatol; 2012 Apr; 22(2):298-302. PubMed ID: 21748365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
